Skip to main content
. 2016 Dec 1;10:157–165. doi: 10.2147/BTT.S114625

Figure 2.

Figure 2

Percentage of patients newly prescribed for erythropoiesis-stimulating agents, stratified by hematologic cancer type at baseline.

Note: *Non-Hodgkin’s lymphoma (grouped together under the diagnosis of other malignant neoplasms of lymphoid and histiocytic tissue and lymphosarcoma and reticulosarcoma and other specified malignant tumors of lymphatic tissue).